NEUROCRINE BIOSCIENCES INC (NBIX) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 6.95%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 6.95% | Share-based compensation / revenue. Period ending 2026-06-30. $234.50M ÷ $3.37B × 100 ≈ 6.95% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | 3.37B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 234.50M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 794.80M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $3.37B | $234.50M | $794.80M | (m) | (m) | 6.95% | (m) | (m) |
| 2026-03-31 | (m) | $3.10B | $222.30M | $788.90M | (m) | (m) | 7.17% | (m) | (m) |
| 2025-12-31 | (m) | $2.86B | $217.90M | $619.10M | (m) | (m) | 7.62% | (m) | (m) |
| 2025-09-30 | (m) | $2.68B | $225.70M | $550.20M | (m) | (m) | 8.41% | (m) | (m) |
| 2025-06-30 | (m) | $2.51B | $213.50M | $495.00M | (m) | (m) | 8.51% | (m) | (m) |
| 2025-03-31 | (m) | $2.41B | $203.80M | $494.80M | (m) | (m) | 8.45% | (m) | (m) |
| 2024-12-31 | (m) | $2.36B | $195.50M | $570.50M | (m) | (m) | 8.30% | (m) | (m) |
| 2024-09-30 | (m) | $2.24B | $167.20M | $578.80M | (m) | (m) | 7.45% | (m) | (m) |
| 2024-06-30 | (m) | $2.12B | $173.50M | $536.20M | (m) | (m) | 8.19% | (m) | (m) |
| 2024-03-31 | (m) | $1.98B | $198.90M | $464.40M | $4.60M | (m) | 10.04% | 100.96× | Reported |
| 2023-12-31 | (m) | $1.89B | $194.30M | $250.90M | $4.60M | (m) | 10.30% | 54.54× | Reported |
| 2023-09-30 | (m) | $1.78B | $199.70M | $204.00M | $4.60M | (m) | 11.19% | 44.35× | Reported |
| 2023-06-30 | (m) | $1.67B | $195.00M | $150.60M | $4.70M | (m) | 11.66% | 32.04× | Reported |
| 2023-03-31 | (m) | $1.60B | $176.00M | $131.70M | $5.60M | (m) | 11.01% | 23.52× | Reported |
| 2022-12-31 | (m) | $1.49B | $173.10M | $249.00M | $7.10M | (m) | 11.63% | 35.07× | Reported |
| 2022-09-30 | (m) | $1.39B | $165.20M | $109.30M | $12.60M | (m) | 11.90% | 8.67× | Reported |
| 2022-06-30 | (m) | $1.30B | $159.20M | $66.00M | $18.00M | (m) | 12.28% | 3.67× | Reported |
| 2022-03-31 | (m) | $1.21B | $138.30M | $74.10M | $22.00M | (m) | 11.45% | 3.37× | Reported |
| 2021-12-31 | (m) | $1.13B | $134.20M | $102.50M | $25.80M | (m) | 11.84% | 3.97× | Reported |
| 2021-09-30 | (m) | $1.07B | $119.60M | $210.60M | $27.00M | (m) | 11.18% | 7.80× | Reported |
| 2021-06-30 | (m) | $1.03B | $109.20M | $121.80M | $28.90M | (m) | 10.58% | 4.21× | Reported |
| 2021-03-31 | (m) | $1.05B | $110.10M | $135.60M | $31.00M | (m) | 10.53% | 4.37× | Reported |
| 2020-12-31 | (m) | $1.05B | $100.00M | $163.00M | $32.80M | (m) | 9.56% | 4.97× | Reported |
| 2020-09-30 | (m) | $1.04B | $100.26M | $139.98M | $33.16M | (m) | 9.62% | 4.22× | Reported |
| 2020-06-30 | (m) | $1.01B | $93.86M | $274.38M | $32.66M | (m) | 9.33% | 8.40× | Reported |
| 2020-03-31 | (m) | $886.79M | $82.26M | $232.18M | $32.26M | (m) | 9.28% | 7.20× | Reported |
| 2019-12-31 | (m) | $788.09M | $75.26M | $72.28M | $31.96M | (m) | 9.55% | 2.26× | Reported |
| 2019-09-30 | (m) | $675.57M | $67.21M | $45.43M | $31.60M | (m) | 9.95% | 1.44× | Reported |
| 2019-06-30 | $173.93M | $605.23M | $60.03M | $9.66M | $31.23M | 28.74% | 9.92% | 0.31× | Reported |
| 2019-03-31 | $149.23M | $518.56M | $53.95M | $-26.66M | $30.88M | 28.78% | 10.40% | -0.86× | Reported |
| 2018-12-31 | $160.52M | $451.24M | $58.07M | $36.90M | $30.53M | 35.57% | 12.87% | 1.21× | Reported |
| 2018-09-30 | $147.03M | $414.26M | $58.25M | $26.86M | $30.19M | 35.49% | 14.06% | 0.89× | Reported |
| 2018-06-30 | $134.01M | $323.28M | $55.39M | $-33.46M | $29.85M | 41.45% | 17.13% | -1.12× | Reported |
| 2018-03-31 | $118.89M | $232.71M | $53.42M | $-88.88M | $27.03M | 51.09% | 22.96% | -3.29× | Reported |
| 2017-12-31 | $121.83M | $161.63M | $42.52M | $-131.36M | $19.52M | 75.38% | 26.31% | -6.73× | Reported |
| 2017-09-30 | $118.80M | $67.11M | $37.02M | $-189.45M | (m) | 177.02% | 55.17% | (m) | (m) |
| 2017-06-30 | $117.28M | $6.33M | $33.14M | $-221.89M | (m) | 1851.22% | 523.09% | (m) | (m) |
| 2017-03-31 | $122.27M | $0.00 | $30.52M | $-206.45M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $94.29M | $15.00M | $28.46M | $-147.37M | (m) | 628.61% | 189.76% | (m) | (m) |
| 2016-09-30 | $93.52M | $15.00M | $26.74M | $-131.87M | (m) | 623.45% | 178.25% | (m) | (m) |
| 2016-06-30 | $96.96M | $15.00M | $34.32M | $-129.28M | (m) | 646.42% | 228.81% | (m) | (m) |
| 2016-03-31 | $88.82M | $15.00M | $31.71M | $-112.77M | (m) | 592.13% | 211.40% | (m) | (m) |
| 2015-12-31 | $81.49M | $19.77M | $28.39M | $-94.20M | (m) | 412.22% | 143.62% | (m) | (m) |
| 2015-09-30 | $75.18M | $19.77M | $24.61M | $-83.92M | (m) | 380.29% | 124.49% | (m) | (m) |
| 2015-06-30 | $62.99M | $19.77M | $13.37M | $-64.94M | (m) | 318.61% | 67.64% | (m) | (m) |
| 2015-03-31 | $54.43M | $19.77M | $11.54M | $-53.97M | (m) | 275.32% | 58.35% | (m) | (m) |
| 2014-12-31 | $46.42M | $0.00 | $10.38M | $-64.41M | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | $39.84M | $730.00K | $9.63M | $-55.47M | (m) | 5458.22% | 1319.73% | (m) | (m) |
| 2014-06-30 | $37.14M | $1.46M | $8.68M | $-50.62M | (m) | 2545.65% | 595.00% | (m) | (m) |
| 2014-03-31 | $37.51M | $2.19M | $7.53M | $-49.43M | (m) | 1713.43% | 344.18% | (m) | (m) |
| 2013-12-31 | $39.25M | $2.92M | $6.82M | $-49.68M | (m) | 1344.57% | 233.61% | (m) | (m) |
| 2013-09-30 | $39.43M | $24.14M | $6.43M | $-29.57M | (m) | 163.35% | 26.65% | (m) | (m) |
| 2013-06-30 | $39.80M | $32.76M | $6.09M | $-21.52M | (m) | 121.47% | 18.59% | (m) | (m) |
| 2013-03-31 | $38.09M | $42.60M | $5.79M | $-9.73M | (m) | 89.40% | 13.58% | (m) | (m) |
| 2012-12-31 | $37.16M | $53.14M | $5.48M | $1.45M | (m) | 69.93% | 10.31% | (m) | (m) |
| 2012-09-30 | $36.07M | $42.30M | $5.08M | $-6.69M | (m) | 85.26% | 12.00% | (m) | (m) |
| 2012-06-30 | $33.66M | $74.58M | $4.61M | $27.71M | (m) | 45.14% | 6.18% | (m) | (m) |
| 2012-03-31 | $33.02M | $76.17M | $3.63M | $30.19M | (m) | 43.35% | 4.77% | (m) | (m) |
| 2011-12-31 | $30.95M | $77.41M | $2.92M | $33.92M | (m) | 39.98% | 3.77% | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $31.15M | $33.50M | $3.13M | $-13.72M | (m) | 92.99% | 9.35% | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $33.72M | $2.95M | $5.54M | $-53.67M | (m) | 1141.96% | 187.57% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |